Testosterone Recovery after Androgen Deprivation Therapy in Prostate Cancer: Building a Predictive Model (doi:10.7910/DVN/9Y2LN7)

View:

Part 1: Document Description
Part 2: Study Description
Part 5: Other Study-Related Materials
Entire Codebook

Testosterone Recovery after Androgen Deprivation Therapy in Prostate Cancer: Building a Predictive Model

doi:10.7910/DVN/9Y2LN7

Harvard Dataverse

2022-02-16

1

Ángel Borque-Fernando, 2022, "Testosterone Recovery after Androgen Deprivation Therapy in Prostate Cancer: Building a Predictive Model", https://doi.org/10.7910/DVN/9Y2LN7, Harvard Dataverse, V1

Testosterone Recovery after Androgen Deprivation Therapy in Prostate Cancer: Building a Predictive Model

doi:10.7910/DVN/9Y2LN7

Ángel Borque-Fernando (Department of Urology, IIS-Aragon, Miguel Servet University Hospital, Paseo Isabel La Católica 12, 50009 Zaragoza, Spain)

Harvard Dataverse

Luis Mariano Esteban

Park, Hyun Jun

2022-02-16

https://doi.org/10.7910/DVN/9Y2LN7

Medicine, Health and Life Sciences, Medicine, Health and Life Sciences

Purpose: To analyze the variability, associated actors, and the design of nomograms for individualized testosterone recovery after cessation of androgen deprivation therapy (ADT). Materials and Methods: A longitudinal study was carried out with 208 patients in the period 2003 to 2019. Castrated and normogonadic testosterone levels were defined as 0.5 and 3.5 ng/mL, respectively. The cumulative incidence curve described the recovery of testosterone. Univariate and multivariate analyzes were performed to predict testosterone recovery with candidate prognostic factors prostate-specific antigen at diagnosis, clinical stage, Gleason score from biopsy, age at cessation of ADT, duration of ADT, primary therapy and use of LHRH (luteinizing hormone-releasing hormone) agonists. Results: The median follow-up duration in the study was 80 months (interquartile range, 49–99 mo). Twenty-five percent and 81% of patients did not recover the castrate and normogonadic levels, respectively. Duration of ADT and age at ADT cessation were significant predictors of testosterone recovery. We built two nomograms for testosterone recovery at 12, 24, 36, and 60 months. The castration recovery model had good calibration. The C-index was 0.677, with area under the receiver operating characteristic curve (AUC-ROC) of 0.736, 0.783, 0.782, and 0.780 at 12, 24, 36, and 60 months, respectively. The normogonadic recovery model overestimated the higher values of probability of recovery. The Cindex was 0.683, with AUC values of 0.812, 0.711, 0.708 and 0.693 at 12, 24, 36, and 60 months, respectively. Conclusions: Depending on the age of the patient and the length of treatment, clinicians may stop ADT and the castrated testosterone level will be maintained or, if the course of treatment has been short, we can estimate if it will return to normogonadic levels.

CC0 Waiver

pISSN: 2287-4208 / eISSN: 2287-4690 World J Mens Health Published online M D, 2022 https://doi.org/10.5534/wjmh.210178

Label:

Database_WJMH (1).csv

text/csv